LOG IN
SIGN UP
MARKET
MNOV
MNOV
Medicinova
NASDAQ
Real-time Quotes | Nasdaq Last Sale
2.490
+0.020
+0.81%
Closed 16:00 05/27 EDT
OPEN
2.600
PREV CLOSE
2.470
HIGH
2.600
LOW
2.460
VOLUME
34.36K
TURNOVER
68.53K
52 WEEK HIGH
5.09
52 WEEK LOW
2.090
MARKET CAP
122.13M
P/E (TTM)
-12.0116
1D
5D
1M
3M
1Y
5Y
MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Plan in Place for Phase 2 Trial of MN-001 in Patients with NAFLD, Type 2 Diabetes, and Hypertriglyceridemia In April 2022, MedicNova, Inc. (NASDAQ:MNOV) announced plans for ...
Zacks Small Cap Research · 2d ago
We're Not Very Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 05/06 13:48
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
LA JOLLA, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD...
GlobeNewswire · 04/21 23:00
MediciNova Says Experimental Cancer Drug Prevented Spread of Disease in Preclinical Trial
MT Newswires · 04/21 04:06
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating th...
GlobeNewswire · 04/20 23:00
MediciNova Completes Patient Enrollment in Mid-Stage Trial in Hospitalized COVID-19 Patients at Risk for ARDS
MT Newswires · 04/13 03:27
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
LA JOLLA, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 cli...
GlobeNewswire · 04/13 03:00
MNOV: Genzyme Patent Litigation Could Lead to Significant Payout…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT
Benzinga · 04/11 15:31
No Data
Learn about the latest financial forecast of MNOV. Analyze the recent business situations of Medicinova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MNOV stock price target is 14.25 with a high estimate of 27.00 and a low estimate of 6.00.
Current 2.490
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
- 0
Institutional Holdings
Institutions: 59
Institutional Holdings: 9.16M
% Owned: 18.68%
Shares Outstanding: 49.05M
TypeInstitutionsShares
Increased
15
486.17K
New
9
303.55K
Decreased
10
764.29K
Sold Out
5
38.23K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Himawan
President/Chief Executive Officer/Director
Yuichi Iwaki
Chief Financial Officer
Douglas Paulin
Chief Scientific Officer
Federico Gaeta
Vice President/IR Contact Officer
Geoffrey O'brien
Other/Director
Kazuko Matsuda
Other
David Crean
Independent Director
Carolyn Beaver
Independent Director
Hideki Nagao
No Data
No Data
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focused on the United States market. It is currently focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). ibudilast is developing for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), and prevention of acute respiratory distress syndrome. tipelukast is developing for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 for solid tumor cancers.
Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.